Adaptive immunity in hepatocellular carcinoma: Prognostic and therapeutic implications

Expert Review of Anticancer Therapy

Volumn 9, Issue 10, 2009, Pages 1499-1510

  Fatourou, Evangelia M ^a   Koskinas, John S ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Chemoembolization; Hepatocellular carcinoma; Immune response; Immunotherapy; Radiofrequency ablation

Indexed keywords

ALCOHOL; ALPHA FETOPROTEIN; BCG VACCINE; CANCER VACCINE; CD3 ANTIBODY; CISPLATIN; DENDRITIC CELL VACCINE; DOXORUBICIN; GELATIN; GLYPICAN 3; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; MELANOMA ANTIGEN; NY ESO 1 ANTIGEN; PLACEBO; SORAFENIB; TUMOR ANTIGEN;

ADAPTIVE IMMUNITY; ANTIGEN EXPRESSION; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER INCIDENCE; CANCER SURVIVAL; CANCER THERAPY; CELL ACTIVATION; CELLULAR IMMUNITY; CHEMOEMBOLIZATION; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOLOGICAL TOLERANCE; LIVER CELL CARCINOMA; LYMPHOCYTIC INFILTRATION; NONHUMAN; OUTCOME ASSESSMENT; PROGNOSIS; RADIOFREQUENCY ABLATION; REVIEW; SUPPRESSOR CELL; SURVIVAL RATE;

ANIMALS; ANTIGENS, NEOPLASM; CARCINOMA, HEPATOCELLULAR; COMBINED MODALITY THERAPY; HUMANS; IMMUNE TOLERANCE; IMMUNITY; IMMUNOTHERAPY; LIVER NEOPLASMS; PROGNOSIS; SURVIVAL RATE; T-LYMPHOCYTES;

EID: 70350586771     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/ERA.09.103     Document Type: Review

References (112)

1. Anthony PP. Hepatocellular carcinoma: an overview. Histopathology 39(2), 109-118 (2001).
2. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int. J. Cancer 94(2), 153-156 (2001).
3. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N. Engl. J. Med. 340(10), 745-750 (1999).
4. Yoo HY, Patt CH, Geschwind JF, Thuluvath PJ. The outcome of liver transplantation in patients with hepatocellular carcinoma in the United States between 1988 and 2001: 5-year survival has improved significantly with time. J. Clin. Oncol. 21(23), 4329-4335 (2003).
5. Tandon P, Garcia-Tsao G. Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies. Liver Int. 29(4), 502-510 (2009).
6. Levy I, Sherman M. Staging of hepatocellular carcinoma: assessment of the CLIP, Okuda, and Child-Pugh staging systems in a cohort of 257 patients in Toronto. Gut 50(6), 881-885 (2002). (Pubitemid 34539054)
7. Mazzaferro V, Regalia E, Doci R et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N. Engl. J. Med. 334(11), 693-699 (1996). (Pubitemid 26079803)
8. Butterfield LH, Koh A, Meng W et al. Generation of human T-cell responses to an HLA-A2.1-restricted peptide epitope derived from α-fetoprotein. Cancer Res. 59(13), 3134-3142 (1999). (Pubitemid 29316013)
9. Butterfield LH, Meng WS, Koh A et al. T cell responses to HLA-A*0201-restricted peptides derived from human a fetoprotein. J. Immunol. 166(8), 5300-5308 (2001). (Pubitemid 32280749)
10. Butterfield LH, Ribas A, Meng WS et al. T-cell responses to HLA-A*0201 immunodominant peptides derived from α-fetoprotein in patients with hepatocellular cancer. Clin. Cancer Res. 9(16 Pt 1), 5902-5908 (2003). (Pubitemid 38018074)
11. Grimm CF, Ortmann D, Mohr L et al. Mouse α-fetoprotein-specific DNA-based immunotherapy of hepatocellular carcinoma leads to tumor regression in mice. Gastroenterology 119(4), 1104-1112 (2000). (Pubitemid 30777930)
12. Chen CH, Huang GT, Lee HS et al. High frequency of expression of MAGE genes in human hepatocellular carcinoma. Liver 19(2), 110-114 (1999).
13. Kariyama K, Higashi T, Kobayashi Y et al. Expression of MAGE-1 and -3 genes and gene products in human hepatocellular carcinoma. Br. J. Cancer 81(6), 1080-1087 (1999). (Pubitemid 29516155)
14. Kobayashi Y, Higashi T, Nouso K et al. Expression of MAGE, GAGE and BAGE genes in human liver diseases: utility as molecular markers for hepatocellular carcinoma. J. Hepatol. 32(4), 612-617 (2000). (Pubitemid 30180381)
15. Chen CH, Chen GJ, Lee HS et al. Expressions of cancer-testis antigens in human hepatocellular carcinomas. Cancer Lett. 164(2), 189-195 (2001).
16. Dong XY, Su YR, Qian XP et al. Identification of two novel CT antigens and their capacity to elicit antibody response in hepatocellular carcinoma patients. Br. J. Cancer 89(2), 291-297 (2003).
17. + T-cell response to HLA-A2-restricted NY-ESO-1b peptide in hepatocellular carcinoma patients. Clin. Cancer Res. 10(20), 6946-6955 (2004).
18. Capurro M, Wanless IR, Sherman M et al. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology 125(1), 89-97 (2003). (Pubitemid 36799110)
19. Mizukoshi E, Nakamoto Y, Marukawa Y et al. Cytotoxic T cell responses to human telomerase reverse transcriptase in patients with hepatocellular carcinoma. Hepatology 43(6), 1284-1294 (2006). (Pubitemid 43980107)
20. + T cells in xenografted nude mice. J. Immunol. 170(3), 1183-1190 (2003).
21. Lee MO, Choi YH, Shin EC et al. Hepatitis B virus X protein induced expression of interleukin 18 (IL-18): a potential mechanism for liver injury caused by hepatitis B virus (HBV) infection. J. Hepatol. 37(3), 380-386 (2002).
22. Borghesi L, Milcarek C. Innate versus adaptive immunity: a paradigm past its prime? Cancer Res. 67(9), 3989-3993 (2007). (Pubitemid 46815040)
23. Ito Y, Takeda T, Umeshita K et al. Fas antigen expression in hepatocellular carcinoma tissues. Oncol. Rep. 5(1), 41-44 (1998). (Pubitemid 28039814)
24. Yuen MF, Hughes RD, Heneghan MA, Langley PG, Norris S. Expression of Fas antigen (CD95) in peripheral blood lymphocytes and in liver-infiltrating, cytotoxic lymphocytes in patients with hepatocellular carcinoma. Cancer 92(8), 2136-2141 (2001). (Pubitemid 32973324)
25. Wada Y, Nakashima O, Kutami R, Yamamoto O, Kojiro M. Clinicopathological study on hepatocellular carcinoma with lymphocytic infiltration. Hepatology 27(2), 407-414 (1998). (Pubitemid 28081054)
26. Liu Y, Daley S, Evdokimova VN et al. Hierarchy of α fetoprotein (AFP)-specific T cell responses in subjects with AFP-positive hepatocellular cancer. J. Immunol. 177(1), 712-721 (2006). (Pubitemid 43939186)
27. + T cell responses in patients with hepatocellular carcinoma. J. Immunol. 174(3), 1709-1716 (2005).
28. Korangy F, Ormandy LA, Bleck JS et al. Spontaneous tumor-specific humoral and cellular immune responses to NY-ESO-1 in hepatocellular carcinoma. Clin. Cancer Res. 10(13), 4332-4341 (2004). (Pubitemid 38878871)
29. + cells in patients with hepatocellular carcinoma. J. Hepatol. 40(1), 102-109 (2004).
30. + T lymphocytes recognizing wild-type p53-derived epitopes in peripheral blood correlate with presence of epitope loss tumor variants in patients with hepatocellular carcinoma. Int. J. Cancer 119(12), 2851-2860 (2006).
31. Kohda H, Sekiya C, Torimoto Y et al. Importance of cytotoxic T lymphocytes in the rejection of transplanted hepatocellular carcinoma. J. Gastroenterol. 29(3), 282-288 (1994). (Pubitemid 24188653)
32. Aruga A, Yamauchi K, Takasaki K, Furukawa T, Hanyu F. Induction of autologous tumor-specific cytotoxic T cells in patients with liver cancer. Characterizations and clinical utilization. Int. J. Cancer 49(1), 19-24 (1991).
33. + T cell responses in patients with hepatocellular carcinoma. Hepatology 48(6), 1821-1833 (2008).
34. Terabe M, Swann J, Ambrosino E et al. A nonclassical non- Vα14Jα18 CD1d-restricted (type II) NKT cell is sufficient for down-regulation of tumor immunosurveillance. J. Exp. Med. 202(12), 1627-1633 (2005). (Pubitemid 41815868)
35. Terabe M, Berzofsky JA. The role of NKT cells in tumor immunity. Adv. Cancer Res. 101, 277-348 (2008).
36. Shibolet O, Alper R, Zlotogarov L et al. NKT and CD8 lymphocytes mediate suppression of hepatocellular carcinoma growth via tumor antigen-pulsed dendritic cells. Int. J. Cancer 106(2), 236-243 (2003). (Pubitemid 36835177)
37. Shibolet O, Alper R, Zlotogarov L et al. Suppression of hepatocellular carcinoma growth via oral immune regulation towards tumor-associated antigens is associated with increased NKT and CD8+ lymphocytes. Oncology 66(4), 323-330 (2004). (Pubitemid 38822803)
38. Zigmond E, Preston S, Pappo O et al. β-glucosylceramide: a novel method for enhancement of natural killer T lymphoycte plasticity in murine models of immune-mediated disorders. Gut 56(1), 82-89 (2007). (Pubitemid 46044892)
39. Margalit M, Shibolet O, Klein A et al. Suppression of hepatocellular carcinoma by transplantation of ex-vivo immune-modulated NKT lymphocytes. Int. J. Cancer 115(3), 443-449 (2005). (Pubitemid 40663749)
40. Miyagi T, Takehara T, Tatsumi T et al. CD1d-mediated stimulation of natural killer T cells selectively activates hepatic natural killer cells to eliminate experimentally disseminated hepatoma cells in murine liver. Int. J. Cancer 106(1), 81-89 (2003). (Pubitemid 36750392)
41. Knutson KL, Disis ML. Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol. Immunother. 54(8), 721-728 (2005).
42. Knutson KL, Disis ML. Augmenting T helper cell immunity in cancer. Curr. Drug Targets Immune Endocr. Metabol. Disord. 5(4), 365-371 (2005).
43. Unitt E, Marshall A, Gelson W et al. Tumour lymphocytic infiltrate and recurrence of hepatocellular carcinoma following liver transplantation. J. Hepatol. 45(2), 246-253 (2006). •• Immunohistochemical analysis in explant tissue of 69 patients who underwent liver transplantation for hepatocellular carcinoma (HCC). Lymphocyte infiltration was associated with prognosis.
44. + helper T-cell responses in healthy donors and HCC patients. J. Immunother. 30(4), 425-437 (2007).
45. Budhu A, Wang XW. The role of cytokines in hepatocellular carcinoma. J. Leukoc. Biol. 80(6), 1197-1213 (2006).
46. Budhu A, Forgues M, Ye QH et al. Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell 10(2), 99-111 (2006). •• This study suggests that a Th1 to Th2 shift in tumor microenvironment may promote HCC metastasis. (Pubitemid 44202603)
47. Wang RF. Regulatory T cells and Toll-like receptors in cancer therapy. Cancer Res. 66(10), 4987-4990 (2006).
48. Sakaguchi S. Regulatory T cells: key controllers of immunologic self-tolerance. Cell 101(5), 455-458 (2000).
49. Morse MA, Clay TM, Mosca P, Lyerly HK. Immunoregulatory T cells in cancer immunotherapy. Expert Opin. Biol. Ther. 2(8), 827-834 (2002).
50. Woo EY, Yeh H, Chu CS et al. Cutting edge: regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J. Immunol. 168(9), 4272-4276 (2002).
51. + immunoregulatory cells. J. Immunol. 167(3), 1137-1140 (2001).
52. + suppressor T cells: more questions than answers. Nat. Rev. Immunol. 2(6), 389-400 (2002).
53. Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune tolerance. Cell 133(5), 775-787 (2008).
54. Dieckmann D, Plottner H, Berchtold S, Berger T, Schuler G. Ex vivo isolation and characterization of CD4(+)CD25(+) T cells with regulatory properties from human blood. J. Exp. Med. 193(11), 1303-1310 (2001). (Pubitemid 32524780)
55. von Boehmer H. Mechanisms of suppression by suppressor T cells. Nat. Immunol. 6(4), 338-344 (2005).
56. Chen ML, Pittet MJ, Gorelik L et al. Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-β signals in vivo. Proc. Natl Acad. Sci. USA 102(2), 419-424 (2005). (Pubitemid 40116782)
57. Fontenot JD, Rudensky AY. A well adapted regulatory contrivance: regulatory T cell development and the forkhead family transcription factor Foxp3. Nat. Immunol. 6(4), 331-337 (2005).
58. Cao M, Cabrera R, Xu Y et al. Hepatocellular carcinoma cell supernatants increase expansion and function of CD4(+) CD25(+) regulatory T cells. Lab. Invest. 87(6), 582-590 (2007). (Pubitemid 46788787)
59. + regulatory T cells in hepatocellular carcinoma patients]. Zhonghua Gan Zang Bing. Za Zhi 15(4), 266-272 (2007).
60. Unitt E, Rushbrook SM, Marshall A et al. Compromised lymphocytes infiltrate hepatocellular carcinoma: the role of T-regulatory cells. Hepatology 41(4), 722-730 (2005). (Pubitemid 40462933)
61. Gao Q, Qiu SJ, Fan J et al. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J. Clin. Oncol. 25(18), 2586-2593 (2007). •• Study of 302 HCC patients who underwent surgical resection. The intratumoral balance of regulatory and cytotoxic T cells was an independent predictor for recurrence and survival. (Pubitemid 47041232)
62. Wolf AM, Wolf D, Steurer M et al. Increase of regulatory T cells in the peripheral blood of cancer patients. Clin. Cancer Res. 9(2), 606-612 (2003). (Pubitemid 36182591)
63. Ormandy LA, Hillemann T, Wedemeyer H et al. Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res. 65(6), 2457-2464 (2005). (Pubitemid 40490158)
64. + regulatory T cells in patients with hepatocellular carcinoma. Eur. J. Surg. Oncol. 34(2), 173-179 (2008).
65. + regulatory T cells affect the development and progression of hepatocarcinogenesis. Clin. Cancer Res. 13(3), 902-911 (2007).
66. + regulatory T-cells in the liver of patients with hepatocellular carcinoma. J. Hepatol. 45(2), 254-262 (2006).
67. Fu J, Xu D, Liu Z et al. Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology 132(7), 2328-2339 (2007). (Pubitemid 46890865)
68. +CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J. Immunol. 173(2), 1444-1453 (2004).
69. Woo EY, Chu CS, Goletz TJ et al. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res. 61(12), 4766-4772 (2001).
70. + regulatory T cells in patients with gastrointestinal malignancies: possible involvement of regulatory T cells in disease progression. Cancer 98(5), 1089-1099 (2003).
71. Curiel TJ, Coukos G, Zou L et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10(9), 942-949 (2004). (Pubitemid 39273735)
72. + T cells in B-cell non-Hodgkin lymphoma. Blood 107(9), 3639-3646 (2006).
73. + regulatory cells results in suppression of melanoma growth and induction of autoreactivity in mice. Cancer Immun. 2, 1 (2002).
74. Gao YW, Chen YX, Wang ZM et al. Increased expression of cyclooxygenase-2 and increased infiltration of regulatory T cells in tumors of patients with hepatocellular carcinoma. Digestion 79(3), 169-176 (2009).
75. Okazaki T, Honjo T. PD-1 and PD-1 ligands: from discovery to clinical application. Int. Immunol. 19(7), 813-824 (2007). (Pubitemid 47241890)
76. + T lymphocytes are prognostic factors of human ovarian cancer. Proc. Natl Acad. Sci. USA 104(9), 3360-3365 (2007).
77. Nomi T, Sho M, Akahori T et al. Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin. Cancer Res. 13(7), 2151-2157 (2007). (Pubitemid 46649885)
78. Gao Q, Wang XY, Qiu SJ et al. Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma. Clin. Cancer Res. 15(3), 971-979 (2009). •• First study regarding the role of PD-L1 status as a new predictor of recurrence in HCC patients.
79. Zabala M, Lasarte JJ, Perret C et al. Induction of immunosuppressive molecules and regulatory T cells counteracts the antitumor effect of interleukin-12-based gene therapy in a transgenic mouse model of liver cancer. J. Hepatol. 47(6), 807-815 (2007). (Pubitemid 350051122)
80. Hoechst B, Ormandy LA, Ballmaier M et al. A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells. Gastroenterology 135(1), 234-243 (2008). (Pubitemid 351899008)
81. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 42(5), 1208-1236 (2005). • Classification and management of HCC according to the Barcelona Clinic Liver Cancer group.
82. Forner A, Bruix J. Locoregional treatment for hepatocellular carcinoma: From clinical exploration to robust clinical data, changing standards of care. Hepatology 47(1), 5-7 (2008). (Pubitemid 351171033)
83. Bruix J. Treatment of hepatocellular carcinoma. Hepatology 25(2), 259-262 (1997).
84. Mazzaferro V, Llovet JM, Miceli R et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol. 10(1), 35-43 (2009).
85. Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359(4), 378-390 (2008). • One of the studies that led to the approval of sorafenib for the treatment of advanced HCC patients.
86. Cheng AL, Kang YK, Chen Z et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a Phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 10(1), 25-34 (2009). • One of the studies that led to the approval of sorafenib for the treatment of advanced HCC patients.
87. Takagi S, Chen K, Schwarz R et al. Functional and phenotypic analysis of tumor-infiltrating lymphocytes isolated from human primary and metastatic liver tumors and cultured in recombinant interleukin-2. Cancer 63(1), 102-111 (1989). (Pubitemid 19031989)
88. Harding CV. Class I MHC presentation of exogenous antigens. J. Clin. Immunol. 16(2), 90-96 (1996).
89. Yamauchi K, Akbar SM, Horiike N, Michitaka K, Onji M. Increased serum levels of macrophage inflammatory protein-3α in hepatocellular carcinoma: relationship with clinical factors and prognostic importance during therapy. Int. J. Mol. Med. 11(5), 601-605 (2003).
90. Hsu TH, Fidler ME, Gill IS. Radiofrequency ablation of the kidney: acute and chronic histology in porcine model. Urology 56(5), 872-875 (2000).
91. Heike M, Weinmann A, Bethke K, Galle PR. Stress protein/peptide complexes derived from autologous tumor tissue as tumor vaccines. Biochem. Pharmacol. 58(9), 1381-1387 (1999). (Pubitemid 29438639)
92. Graner MW, Zeng Y, Feng H, Katsanis E. Tumor-derived chaperone-rich cell lysates are effective therapeutic vaccines against a variety of cancers. Cancer Immunol. Immunother. 52(4), 226-234 (2003). (Pubitemid 36535282)
93. Bustin M. At the crossroads of necrosis and apoptosis: signaling to multiple cellular targets by HMGB1. Sci. STKE 2002(151), E39 (2002).
94. Hansler J, Wissniowski TT, Schuppan D et al. Activation and dramatically increased cytolytic activity of tumor specific T lymphocytes after radio-frequency ablation in patients with hepatocellular carcinoma and colorectal liver metastases. World J. Gastroenterol. 12(23), 3716-3721 (2006). (Pubitemid 43958380)
95. Zerbini A, Pilli M, Penna A et al. Radiofrequency thermal ablation of hepatocellular carcinoma liver nodules can activate and enhance tumor-specific T-cell responses. Cancer Res. 66(2), 1139-1146 (2006). •• Comprehensive analysis of T-cell responses before and after radiofrequency ablation. (Pubitemid 43165983)
96. Ostapenko VV, Tanaka H, Miyano M et al. Immune-related effects of local hyperthermia in patients with primary liver cancer. Hepatogastroenterology 52(65), 1502-1506 (2005). (Pubitemid 41391025)
97. den Brok MH, Sutmuller RP, Nierkens S et al. Efficient loading of dendritic cells following cryo and radiofrequency ablation in combination with immune modulation induces anti-tumour immunity. Br. J. Cancer 95(7), 896-905 (2006). (Pubitemid 44498106)
98. Schueller G, Stift A, Friedl J et al. Hyperthermia improves cellular immune response to human hepatocellular carcinoma subsequent to co-culture with tumor lysate pulsed dendritic cells. Int. J. Oncol. 22(6), 1397-1402 (2003).
99. Ali MY, Grimm CF, Ritter M et al. Activation of dendritic cells by local ablation of hepatocellular carcinoma. J. Hepatol. 43(5), 817-822 (2005). (Pubitemid 41414507)
100. Akizuki, A, Magara, T, Tanaka T. Diminution of the number of γδ T lymphocytes in hepatocellular carcinoma patients treated with transcatheter arterial embolization. Nihon Rinsko Meneki Gakkai Kaishi 2, 108-117 (1998).
101. Ayaru L, Pereira SP, Alisa A et al. Unmasking of α-fetoprotein- specific CD4(+) T cell responses in hepatocellular carcinoma patients undergoing embolization. J. Immunol. 178(3), 1914-1922 (2007).
102. Salvadori S, Martinelli G, Zier K. Resection of solid tumors reverses T cell defects and restores protective immunity. J. Immunol. 164(4), 2214-2220 (2000). (Pubitemid 30108782)
103. + patients with hepatocellular carcinoma. Int. J. Cancer 118(5), 1194-1204 (2006).
104. Butterfield LH, Ribas A, Dissette VB et al. A Phase I/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four α-fetoprotein peptides. Clin. Cancer Res. 12(9), 2817-2825 (2006). (Pubitemid 43752122)
105. Palmer DH, Midgley RS, Mirza N et al. A Phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma. Hepatology 49(1), 124-132 (2009).
106. Butterfield LH, Ribas A, Potter DM, Economou JS. Spontaneous and vaccine induced AFP-specific T cell phenotypes in subjects with AFP-positive hepatocellular cancer. Cancer Immunol. Immunother. 56(12), 1931-1943 (2007).
107. Kuang M, Peng BG, Lu MD et al. Phase II randomized trial of autologous formalin-fixed tumor vaccine for postsurgical recurrence of hepatocellular carcinoma. Clin. Cancer Res. 10(5), 1574-1579 (2004). (Pubitemid 38435545)
108. Lee WC, Wang HC, Hung CF et al. Vaccination of advanced hepatocellular carcinoma patients with tumor lysate-pulsed dendritic cells: a clinical trial. J. Immunother. 28(5), 496-504 (2005).
109. Peng BG, Liang LJ, He Q et al. Tumor vaccine against recurrence of hepatocellular carcinoma. World J. Gastroenterol. 11(5), 700-704 (2005). (Pubitemid 40220761)
110. Takayama T, Sekine T, Makuuchi M et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet 356(9232), 802-807 (2000). •• One of the largest and most important immunotherapy trials. A total of 150 patients who had undergone curative resection for HCC were randomized to receive adoptive immunotherapy or no adjuvant treatment. The immunotherapy group had significantly longer recurrence-free survival and disease-specific survival. (Pubitemid 30706677)
111. Iwashita Y, Tahara K, Goto S et al. A Phase I study of autologous dendritic cell-based immunotherapy for patients with unresectable primary liver cancer. Cancer Immunol. Immunother. 52(3), 155-161 (2003). (Pubitemid 36384715)
112. Ladhams A, Schmidt C, Sing G et al. Treatment of non-resectable hepatocellular carcinoma with autologous tumor-pulsed dendritic cells. J. Gastroenterol. Hepatol. 17(8), 889-896 (2002).